Korro Bio
Company Type: Therapeutic development
Main focus: Developing RNA editing platforms to treat various diseases
Company stage: Clinical
Diseases: Alpha-1 antitrypsin deficiency, Parkinson’s disease, Amyotrophic lateral sclerosis, and other rare and prevalent diseases
Genome-editing tool: Oligonucleotide promoted editing of RNA (OPERA®)
Funding stage: Post-IPO Equity
Location: Cambridge, Massachusetts, USA
Website: www.korrobio.com
Pipeline: www.korrobio.com/pipeline/
Partners:
Korro Bio is a biopharmaceutical company focused on the development of RNA editing tools to produce novel genetic therapeutics for the treatment of various diseases. The company’s scientific approach involves harnessing naturally occurring mechanisms of RNA editing via an oligonucleotide-based method to edit a single base in the genome. Korro Bio’s pipeline currently includes a trial for KRRO-110, a potential treatment for alpha-1 antitrypsin deficiency (AATD).